{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:52:06Z","timestamp":1789761126099,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.clml.2019.10.006","type":"journal-article","created":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T21:52:59Z","timestamp":1571521979000},"page":"137-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["18F-FDG PET\/CT or PET Role in MALT Lymphoma: An Open Issue not Yet Solved\u2014A Critical Review"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-666X","authenticated-orcid":false,"given":"Rexhep","family":"Durmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giubbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.10.006_bib1","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3","article-title":"Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma","volume":"50","author":"Isaacson","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.10.006_bib2","series-title":"Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours, Pathology, and Genetics","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.clml.2019.10.006_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib4","first-page":"1134","article-title":"MALT lymphomas: pathogenesis can drive treatment","volume":"25","author":"Bertoni","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2019.10.006_bib5","first-page":"86","article-title":"The management of nongastric MALT lymphomas","volume":"28","author":"Zucca","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2019.10.006_bib6","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib7","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2152","article-title":"Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis","volume":"33","author":"Treglia","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2019.10.006_bib10","first-page":"37","article-title":"Diagnostic role of 18F-FDG PET in gastric MALT lymphoma","volume":"9","author":"Ambrosini","year":"2006","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1016\/j.clml.2019.10.006_bib11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1023\/A:1008312726163","article-title":"Positron emission tomography with fluorine-18\u20132-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type","volume":"10","author":"Hoffmann","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000070290","article-title":"18F-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma","volume":"64","author":"Hoffmann","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2019.10.006_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdi093","article-title":"FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases","volume":"16","author":"Beal","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluorodeoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.10.006_bib15","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/annonc\/mdl295","article-title":"18F-Fluoro-deoxyglucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference","volume":"17","author":"Hoffmann","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib16","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1080\/10428190600733499","article-title":"18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma","volume":"47","author":"Alinari","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.10.006_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdl468","article-title":"Role of radiation therapy in the treatment of stage I\/II mucosa-associated lymphoid tissue lymphoma","volume":"18","author":"Tsai","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-0609.2007.00895.x","article-title":"Diagnostic accuracy of PET\/CT in patients with extranodal marginal zone MALT lymphoma","volume":"79","author":"Perry","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.10.006_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","article-title":"The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-PET with (67)gallium scintigraphy in the evaluation of lymphoma","volume":"110","author":"Tsukamoto","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.10.006_bib20","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s00259-008-0771-8","article-title":"FDG avidity and PET\/CT patterns in primary gastric lymphoma","volume":"35","author":"Radan","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2019.10.006_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12149-007-0125-9","article-title":"Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings","volume":"22","author":"Enomoto","year":"2008","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clml.2019.10.006_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hon.905","article-title":"18F-FDG uptake and its clinical relevance in primary gastric lymphoma","volume":"28","author":"Yi","year":"2010","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"18)F-FDG avidity in lymphoma readdressed: a study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clml.2019.10.006_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hon.2039","article-title":"Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens","volume":"31","author":"Zinzani","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1179\/102453312X13221316477813","article-title":"Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience","volume":"17","author":"Zanni","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2019.10.006_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/RLU.0b013e3182393580","article-title":"Comparison between endoscopic macroscopic classification and F-18 FDG PET findings in gastric mucosa-associated lymphoid tissue lymphoma patients","volume":"37","author":"Hirose","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clml.2019.10.006_bib27","doi-asserted-by":"crossref","first-page":"e50914","DOI":"10.1371\/journal.pone.0050914","article-title":"SUVmax\/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma","volume":"7","author":"Fu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.10.006_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12185-012-1225-4","article-title":"18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential","volume":"97","author":"Watanabe","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2019.10.006_bib29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3109\/10428194.2013.826353","article-title":"Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma","volume":"55","author":"Nasser","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.10.006_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hon.2181","article-title":"Role of 18F-FDG-PET\/CT in the management of marginal zone B cell lymphoma","volume":"33","author":"Carrillo-Cruz","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib31","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.3109\/10428194.2015.1030640","article-title":"18F-Fluorodeoxyglucose (FDG)-positron emission tomography\/computed tomography in mucosa associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement","volume":"56","author":"Park","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.10.006_bib32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4166\/kjg.2016.67.4.183","article-title":"Efficacy of positron emission tomography\/computed tomography in gastric mucosa-associated lymphoid tissue lymphoma","volume":"67","author":"Hwang","year":"2016","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.clml.2019.10.006_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RLU.0000000000001005","article-title":"Does delayed time-point imaging improve 18F-FDG PET in patients with MALT lymphoma? Observations in a series of 13 patients","volume":"41","author":"Mayerhoefer","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clml.2019.10.006_bib34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00259-016-3518-y","article-title":"18F-FDG PET\/CT in gastric MALT lymphoma: a bicentric experience","volume":"45","author":"Albano","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2019.10.006_bib35","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1080\/10428194.2017.1298754","article-title":"18F-FDG PET\/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation","volume":"58","author":"Albano","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.10.006_bib36","doi-asserted-by":"crossref","first-page":"20170311","DOI":"10.1259\/bjr.20170311","article-title":"Pulmonary mucosa-associated lymphoid tissue lymphoma: 18F-FDG PET\/CT and CT findings in 28 patients","volume":"90","author":"Albano","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clml.2019.10.006_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/bloodadvances.2017013698","article-title":"Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma","volume":"2","author":"Qi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.10.006_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.2578","article-title":"FDG PET\/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma","volume":"37","author":"Vaxman","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.5009\/gnl.2011.5.3.308","article-title":"Role of 18F-FDG PET scans in patients with Helicobacter pylori-infected gastric low-grade MALT lymphoma","volume":"5","author":"Song","year":"2011","journal-title":"Gut Liver"},{"key":"10.1016\/j.clml.2019.10.006_bib40","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/RLU.0000000000001395","article-title":"Can interim 18F-FDG PET or diffusion-weighted MRI predict end-of-treatment outcome in FDG-avid MALT lymphoma after rituximab-based therapy?: a preliminary study in 15 patients","volume":"41","author":"Mayerhoefer","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clml.2019.10.006_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hon.2414","article-title":"Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL)","volume":"36","author":"Park","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/MNM.0000000000000579","article-title":"Prognostic value of SUVmax measured by pretreatment 18F-FDG PET\/CT in patients with primary gastric lymphoma","volume":"37","author":"Hwang","year":"2016","journal-title":"Nucl Med Comm"},{"key":"10.1016\/j.clml.2019.10.006_bib43","doi-asserted-by":"crossref","unstructured":"Mayerhoefer ME, Staudenherz A, Kiesewetter B, et\u00a0al. Pre-therapeutic total lesion glycolysis on [18F]FDG-PET enables prognostication of 2-year progression-free survival in MALT lymphoma patients treated with CD20-antibody-based immunotherapy [e-pub ahead of print]. Mol Imaging Biol https:\/\/doi.org\/10.1007\/s11307-019-01329-2, accessed.","DOI":"10.1007\/s11307-019-01329-2"},{"key":"10.1016\/j.clml.2019.10.006_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hon.2563","article-title":"Prognostic role of baseline 18F-FDG PET\/CT parameters in MALT lymphoma","volume":"37","author":"Albano","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib45","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1007\/s00261-016-0800-1","article-title":"18F-FDG PET\/CT and primary hepatic MALT: a case series","volume":"41","author":"Albano","year":"2016","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.clml.2019.10.006_bib46","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hon.2376","article-title":"Role of fluorine-18-fluorodeoxyglucose positron emission tomography\/computed tomography in evaluating breast mucosa-associated lymphoid tissue lymphoma: a case series","volume":"35","author":"Albano","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.006_bib47","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/j.clml.2019.03.005","article-title":"Correlations between imaging biomarkers and proliferation index Ki-67 in lymphomas: a systematic review and meta-analysis","volume":"19","author":"Meyer","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.10.006_bib48","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.10.006_bib49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s12149-019-01338-9","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma","volume":"33","author":"Albano","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clml.2019.10.006_bib50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00259-017-3907-x","article-title":"Combination of baseline FDG PET\/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma","volume":"45","author":"Toledano","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2019.10.006_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma","volume":"46","author":"Albano","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2019.10.006_bib52","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","article-title":"Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma","volume":"32","author":"Albano","year":"2018","journal-title":"Ann Nucl Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:35:25Z","timestamp":1730529325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019320336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S2152265019320336"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.10.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18F-FDG PET\/CT or PET Role in MALT Lymphoma: An Open Issue not Yet Solved\u2014A Critical Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}